U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H36N6O6S.ClH
Molecular Weight 633.159
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRAGASTRIN HYDROCHLORIDE

SMILES

Cl.CSCC[C@H](NC(=O)[C@@H](N)CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC3=CC=CC=C3)C(N)=O

InChI

InChIKey=BABSBRZDEYUBSD-RJPXAACDSA-N
InChI=1S/C29H36N6O6S.ClH/c1-42-12-11-22(33-27(39)20(30)14-18-16-32-21-10-6-5-9-19(18)21)28(40)35-24(15-25(36)37)29(41)34-23(26(31)38)13-17-7-3-2-4-8-17;/h2-10,16,20,22-24,32H,11-15,30H2,1H3,(H2,31,38)(H,33,39)(H,34,41)(H,35,40)(H,36,37);1H/t20-,22-,23-,24-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C29H36N6O6S
Molecular Weight 596.698
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tetragastrin is a C-terminal tetrapeptide (Trp–Met–Asp–Phe–NH2) of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin. It is used to test the secretion of digestive juice. It causes severe anxiety symptoms when administered to humans and is commonly used in scientific research to induce panic attacks for the purpose of testing new anxiolytic drugs. Tetragastrin is a selective cholecystokinin B (CCKB) receptor agonist. Tetragastrin is used as a gastric stimulant at a dose of 4 ug/kg, it was marketed in Japan under the brand name Gastopsin.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
19.5 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Gastopsin

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
after overnight fasting, 4 ug/kg by intramuscular injection.
Route of Administration: Intramuscular
In Vitro Use Guide
CCK-4 (0.3 and 1.5 uM) enhanced significantly the K(+)-stimulated release of [(3)H]GABA from rat amygdala slices.
Substance Class Chemical
Record UNII
130LLV7CL9
Record Status Validated (UNII)
Record Version